cardiovascular prevention

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathcardiovascular events

ACAT inhibition

pactimibe
CAPTIVATE, 2009      NCTpactimibeplaceboLow risk of bias -
ACTIVATE, 2006      NCTpactimibeplaceboLow risk of bias -

anticoagulant

not classified
MacMillan, 1960   anticoagulantno anticoagulant -
Borchegrevink, 1960   anticoagulantno anticoagulant -
Clausen, 1961   anticoagulantno anticoagulant -
Harvald, 1961   anticoagulantno anticoagulant -
Conrad, 1964     anticoagulantno anticoagulant -
Wasserman, 1966   anticoagulantno anticoagulant -
Loeliger, 1967   anticoagulantno anticoagulant -
Lovell, 1967   anticoagulantno anticoagulant -
Seaman, 1969     anticoagulantno anticoagulant -
Sorensen, 1969   anticoagulantno anticoagulant -
Meuwisse,, 1969   anticoagulantno anticoagulant -
Drapkin and Merskey, 1972     anticoagulantno anticoagulant -
Sixty Plus Reinfarction, 1980   coumarin congenersplaceboLow risk of bias -
ASPECT, 1994   nicoumalone or phenprocoumonplacebo -
Breddin, 1980   phenprocoumonplaceboLow risk of bias -
dicoumarol
Apenstrom and Korsan-Bengtsen, 1964   dicoumarolno anticoagulant -
rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias - 8100%
wafarin
WARIS, 1990   warfarinplaceboLow risk of bias -
warfarin
Thrombosis Prevention trial (Warfarin), 1998        NCTwarfarinplaceboprimary preventionLow risk of bias suggesting -17%
Thrombosis Prevention trial (W plus A), 1998        NCTwarfarin + aspirinplaceboprimary preventionLow risk of bias suggesting -7%

antioxydants

not classified
Tepel, 2003     acetylcysteineplaceboLow risk of bias suggesting9%-40%
HPS antioxidant, 2002     combinationplaceboLow risk of bias negative4%0%
WAVE (Waters), 2002     combinationplaceboLow risk of bias negative 165%56%
POPADAD (antioxydant), 2008   combinationplaceboLow risk of bias negative 43%
PHS II beta carotene, 2003          NCTcombinationplaceboLow risk of bias -
SUVIMAX, 2005     combinationplaceboLow risk of bias negative-22%-1%
HATS, 2001     combinationplaceboLow risk of bias negative-10%-32%
MVP, 1997     combinationplaceboLow risk of bias negative1%
PHS II (multivitamin), 2012        NCTcombinationplaceboLow risk of bias negative-5%
ARISE, 2008      NCTsuccinobucol placeboLow risk of bias suggesting 0%
beta carotene
ATBC beta carotene, 1994     beta caroteneplaceboLow risk of bias -
CARET beta carotene, 1996       beta caroteneplaceboLow risk of bias negative 17%
SCP beta carotene, 1990   beta caroteneplaceboLow risk of bias negative7%
NSCP (Green) beta carotene, 1999     beta caroteneplaceboLow risk of bias negative-49%
PHS beta carotene, 1996     beta caroteneplaceboLow risk of bias suggesting-91%-91%
WHS beta carotene, 1999        NCTbeta caroteneplaceboLow risk of bias negative7%14%
WACS beta-caroten, 2007        NCTbeta caroteneplaceboLow risk of bias negative3%9%
ATBC 2nd prev subgroup (b carotene), 1998     beta caroteneplaceboLow risk of bias negative
vitamin c
WACS vitamin C, 2007        NCTvitamin CplaceboLow risk of bias negative3%1%
PHS II vitamin C, 2008    NCTvitamin CplaceboLow risk of bias negative6%-1%
vitamin e
GISSI, 1999     vitamin EcontrolRisk of bias negative-8%-2%
PPP, 2001     vitamin EcontrolRisk of bias negative7%7%
ATBC vitamin E, 1994     vitamin EplaceboLow risk of bias suggesting-2%
CHAOS, 1996   vitamin EplaceboLow risk of bias suggesting29%-40%
HOPE, 2000     vitamin EplaceboLow risk of bias negative5%
AREDS, 2001     vitamin EplaceboLow risk of bias negative5%
Linxian, 1993     vitamin Eplacebonegative-9%
WACS vitamin E, 2007        NCTvitamin EplaceboLow risk of bias negative2%-8%
PHS II vitamin E, 2008    NCTvitamin EplaceboLow risk of bias negative 3%-1%
WHS vitamin E, 2005      NCTvitamin EplaceboLow risk of bias negative
ASAP, 2000         vitamin EplaceboLow risk of bias negative100%
SPACE, 2000     vitamin EplaceboLow risk of bias suggesting9%-46%
HOPE renal insufficiency subgroup, 2004     vitamin EplaceboLow risk of bias negative-10%4%
ATBC 2nd prev subgroup (vitamin E), 1998       vitamin EplaceboLow risk of bias negative

antiplatelets drug

aspirin
JPAD, 2008      NCTaspirinno treatmentRisk of bias suggesting-20%
PPP (diabetics sub group), 2003   aspirinno treatmentExploratory negative23%-10%
British Doctor’s Trial, 1988   aspirinno treatmentprimary preventionRisk of bias negative-11%-2%
Primary Prevention Project, 2001     aspirinno treatmentprimary preventionRisk of bias negative -19%-28%
POPADAD aspirin, 2008     aspirinplaceboLow risk of bias negative-7%-1%
DAMAD, 1989   aspirinplaceboLow risk of bias negative -51%48%
ETDRS, 1992   aspirinplaceboLow risk of bias suggesting-7%-5%
PHS (diabetics sub group), 1989   aspirinplaceboLow risk of bias suggesting
WHS (diabetics sub group), 2005   aspirinplaceboLow risk of bias suggesting-7%
Physicians Health Study, 1989    NCTaspirinplaceboprimary preventionLow risk of bias suggesting -4%-17%
Thrombosis Prevention Trial, 1998        NCTaspirinplaceboprimary preventionLow risk of bias suggesting3%-12%
HOT, 1998     aspirinplaceboprimary preventionLow risk of bias suggesting -7%-14%
Women’s Health Study, 2005       aspirinplaceboprimary preventionLow risk of bias suggesting -5%-9%
AAA, 2009     aspirinplacebosecondary preventionLow risk of bias negative-5%
ASPREE, 2018    NCTaspirinplacebo -
ASCEND, 2018      NCTaspirinplacebosuggesting -12%
Schoop, 1983   aspirinplaceboLow risk of bias -
Hess, 1985   aspirinplacebo -
Munich A, 1975   aspirinplaceboLow risk of bias -
Munich B, 1975   aspirinplaceboLow risk of bias -
CLIPS, 2007     aspirinplaceboLow risk of bias suggesting71%
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%
JAMIS, 1999     aspirinplacebosuggesting18%
SAPAT, 1992   aspirinplaceboLow risk of bias suggesting-29%
clopidogrel
CAPRIE, 1996   clopidogrelaspirinsecondary preventionLow risk of bias suggesting-2%-8%
CAPRIE (PAD subgroup), 1996   clopidogrelaspirinLow risk of bias suggesting-19%
ASCET    NCTclopidogrelaspirinRisk of bias negative-10%
CHARISMA, 2006      NCTclopidogrelplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -1%-7%
dipyridamol
Atlanta (Sbar), 1967   dipyridamolcontrolLow risk of bias negative25%
Becker, 1967   dipyridamolcontrolLow risk of bias negative+Infini%
Wirecki, 1967   dipyridamolcontrolLow risk of bias negative
Hess (2), 1985   aspirin + dipyridamolplaceboLow risk of bias -
Schoop (2), 1983   aspirin + dipyridamolplaceboLow risk of bias -
VA study, 1986   aspirin + dipyridamolplaceboLow risk of bias -
Igloe, 1970   dipyridamolplaceboLow risk of bias -
Zion, 1961   dipyridamolplaceboLow risk of bias -
Kinsella, 1962   dipyridamolplaceboLow risk of bias -
Leiberman, 1964   dipyridamolplaceboLow risk of bias -
Dewar, 1961   dipyridamolplaceboLow risk of bias -
Neumann, 1964   dipyridamolplaceboLow risk of bias -
Foulds, 1960   dipyridamolplaceboLow risk of bias -
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative
ketanserine
PACK, 1996   ketanserineplaceboLow risk of bias -
Walden, 1991   ketanserineplaceboLow risk of bias -
Thulesius, 1987   ketanserineplaceboLow risk of bias -
picotamide
Cocozza, 1995     picotamideplaceboLow risk of bias negative-100%
ADEP, 1993   picotamideplaceboLow risk of bias -
Neirotti, 1994   picotamideplaceboLow risk of bias -
Coto, 1989   picotamideplaceboLow risk of bias -
sulfinpyrazone
Dutch, 1980   sulfinyrazoneplacebonegative+Infini%107%
suloctidil
Adriaensen, 1976   suloctidilplaceboLow risk of bias -
Verhaeghe, 1981   suloctidilplaceboLow risk of bias -
Jones, 1982   suloctidilplaceboLow risk of bias -
Holm, 1984   suloctidilplaceboLow risk of bias -
ticagrelor
EUCLID, 2016        NCTticagrelorclopidogrelLow risk of bias -
PEGASUS 60mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -11%-15%
PEGASUS 90mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting 0%-15%
ticlopidine
Birmingham-A, 1979   ticlopidineplacebonegative-100%
London diabetes, 1983   ticlopidineplacebonegative5%-47%
TIMAD, 1984   ticlopidineplacebonegative-27%-44%
BTRS, 1992   ticlopidineplaceboLow risk of bias negative-100%
Nyberg, 1984   ticlopidineplaceboLow risk of bias negative+Infini%+Infini%
EMATAP, 1993   ticlopidineplaceboLow risk of bias -
Katsumara, 1982   ticlopidineplaceboLow risk of bias -
Aukland, 1982   ticlopidineplaceboLow risk of bias -
Stiegler, 1984   ticlopidineplaceboLow risk of bias -
Ellis, 1986   ticlopidineplaceboLow risk of bias -
Cloarec, 1986   ticlopidineplaceboLow risk of bias -
Arcan, 1988   ticlopidineplaceboLow risk of bias -
Balsano, 1989   ticlopidineplaceboLow risk of bias -
STIMS, 1990   ticlopidineplaceboLow risk of bias -
Hurlow, 1980   ticlopidineplaceboLow risk of bias -
Krause, 1980   ticlopidineplaceboLow risk of bias -
Berglund, 1985   ticlopidineplaceboLow risk of bias negative
various
CRAMPS, 2000   cloricromeneplaceboLow risk of bias -
vorapaxar
TRA-2P TIMI 50, 2012        NCTvorapaxarplacebo (on top aspirin)secondary preventionLow risk of bias suggesting